The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|August 8, 2013
ScinoPharm, Sundia MediTech Partner for Pharma Outsourcing in China
Author(s)Pharmaceutical Technology Editors
ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.
Advertisement
This cooperation combines Sundia’s capabilities in new drug R&D with ScinoPharm’s process R&D and commercial production expertise, especially in the field of highly potent oncological APIs. Under the alliance, both parties will be able to further support customer needs with one-stop solutions for integrated services such as drug development, research, clinical trials, and commercial manufacturing.
Sondia MediTech is a Shanhai-based CRO with a research team of 600 employees. ScinoPharm Changsho, located in the Jiangsu Province in China is a subsidiary of ScinoPharm Taiwan.
Source:
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement